| 2016-10 |
Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor |
Cancer Research and Treatment. 2016 Oct;48(4):1155-1166. |
 |
| 2016-10 |
BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia |
Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333. |
|
| 2016-10 |
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b |
Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):259. |
|
| 2016-10 |
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge |
Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):260. |
|
| 2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 622PD. |
|
| 2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther |
Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P. |
|
| 2016-10 |
CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma |
Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P. |
|
| 2016-09 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer |
Oncotarget. 2016 Sep;7(38):61136-61151. |
|
| 2016-09 |
Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t |
Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04. |
|
| 2016-08 |
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma |
Journal of Hepatology. 2016 Aug;65(2):296-304. |
|
| 2016-07 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer |
Expert Opinion on Pharmacotherapy. 2016 Jul;17(10):1413-1420. |
|
| 2016-06 |
Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study |
Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84. |
|
| 2016-06 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine |
Annals of Oncology. 2016 Jun;27(Suppl. 2):119. |
|
| 2016-06 |
Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2016 Jun;27(Suppl. 2):110. |
|
| 2016-05-14 |
Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply |
Lancet. 2016 May 14-20;387(10032):1997. |
|
| 2016-05-03 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer |
Scientific Reports. 2016 May 3;6:Article number 25369. |
|
| 2016-05 |
Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma |
Oncotarget. 2016 May;7(21):31122-31136. |
|
| 2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine |
Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126. |
|
| 2016-05 |
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740. |
|
| 2016-05 |
Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC) |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017. |
|
| 2016-05 |
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732. |
|
| 2016-05 |
Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e19024. |
|
| 2016-03 |
miR-520h is crucial for DAPK2 regulation and breast cancer progression |
Oncogene. 2016 Mar 3;35(9):1134-1142. |
|
| 2016-03 |
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer |
Oncogene. 2016 May;35(12):1517-1528. |
|
| 2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial |
Lancet. 2016 Feb;387(10018):545-557. |
|
| 2016-02 |
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells |
RNA. 2016 Feb;22(2):303-315. |
|
| 2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Oncology Research and Treatment. 2016 Feb;39(Suppl. 1):170. |
|
| 2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 134. |
|
| 2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 369. |
|
| 2016-02 |
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract TPS482. |
|
| 2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 417. |
|
| 2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745. |
|
| 2016-01 |
Investigating the association between periodontal disease and risk of pancreatic cancer |
Pancreas. 2016 Jan;45(1):134-141. |
|
| 2016-01 |
S-1 with leucovorin for gastric cancer: How far can it go? |
Lancet Oncology. 2016 Jan;17(1):12-14. |
|
| 2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial |
Medicine. 2016 Jan;95(3):Article number e2565. |
|
| 2015-12-21 |
G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation |
Scientific Reports. 2015 Dec 21;5:Article number 18709. |
|
| 2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial |
Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99. |
|
| 2015-10 |
Epigenetic regulation in the carcinogenesis of cholangiocarcinoma |
International Journal of Biochemistry and Cell Biology. 2015 Oct;67:110-114. |
|
| 2015-10 |
Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells |
Cancer Cell International. 2015 Oct;15:Article number 98. |
|
| 2015-09 |
AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-kappaB activation |
Leukemia and Lymphoma. 2015 Sep;56(9):2674-2682. |
|
| 2015-09 |
The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan |
European Journal of Cancer. 2015 Sep;51(Suppl. 3):S459. |
|
| 2015-09 |
Expression of the Helicobater pylori CagA protein is closely associated with Helicobater pylori-dependence of early-stage high-grade gastric lymphoma |
European Journal of Cancer. 2015 Sep;51(Suppl. 3):S662. |
|
| 2015-08 |
Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: A case report |
Oncology Letters. 2015 Aug;10(4):2366-2370. |
|
| 2015-08 |
The association between periodontal disease and pancreatic cancer |
Cancer Research. 2015 Aug;75:Abstract number 871. |
|
| 2015-07 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review |
Cancer Research and Treatment. 2015 Jul;47(3):343-361. |
|
| 2015-06 |
Helicobacter pylori CagA translocation is closely associated with the expression of CagA-signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphoma |
American Journal of Surgical Pathology. 2015 Jun;39(6):761-766. |
|
| 2015-06 |
Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan |
Medicine. 2015 Jun;94(24):Article number e969. |
|
| 2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer |
Annals of Oncology. 2015 May;26(5):943-949. |
|
| 2015-05 |
Heterogeneous cell origin of helicobater pylori-dependent high-grade gastric lymphomas |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):e19520. |
|
| 2015-05 |
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4101. |
|
